

IAP9 Rec'd PCT/PTO 25 AUG 2006

" Means for a quantitative detection of cytochrome c "

The invention relates to means for detecting cytochrome c release from mitochondria in a biological sample to be tested.

Mitochondria play a central role in the regulation of cellular apoptosis through release of proteins into cytosol.

5 Since the anti-apoptotic protein Bcl-2 was found to reside in mitochondria, scientists started to consider this organelle as important player in apoptosis. Two main findings reinforced the connection between Bcl-2, mitochondria and apoptosis: Bcl-2 was found to prevent the drop in mitochondrial membrane potential ( $\Delta\Psi_m$ ) observed during TNF-induced apoptosis in many  
10 cell types. In the meantime, Newmeyer et al. discovered that a mitochondrial factor was required for the activation of caspases. This factor, released from mitochondria during apoptosis, was later identified as cytochrome c.

15 Two main apoptotic pathways have been described over the past few years : the death-receptor pathway and the mitochondrial pathway. The first is engaged by death receptors which, upon binding to their appropriate ligands, form a death-inducing signalling complex, resulting in pro-caspase-8  
20 activation. In type I cells (T-Lymphocytes), caspase-8 cleaves downstream caspases that execute the cell. In type II (Hepatocytes), caspase-8 cleaves Bid, a BH3-only protein whose C-terminal fragment translocates to mitochondria to engage the mitochondrial pathway. Independently of death-receptor  
25 activation, the mitochondrial pathway can also be activated in response to a large number of death stimuli including DNA damage, topoisomerase inhibition or trophic-factor depletion. This process culminates in the release of mitochondrial proteins from the intermembrane space into the cytosol.

30

Wang's group showed that induction of caspase activity was dependent on the presence of cytochrome c released during the

preparation of the cytosolic extract. Upon cytochrome c binding, Apaf-1 (apoptotic protease-activating factor 1) undergoes conformational changes and activates pro-caspase-9, leading to cell death.

5 Many laboratories over the world, interested in the mechanisms of apoptosis, are studying cytochrome c release in biological preparations (mitochondrial supernatants, cytosol extracts, etc) this release being a hallmark for apoptosis execution. Therefore, cytochrome c detection has a great  
10 interest for discovering pro- or anti-apoptotic drugs, integrated in screening strategies, alone or combined with other measurements ( $\Delta\Psi_m$ , mitochondrial swelling, etc).

This type of investigations is commonly conducted using immunodetection (for instance Western blotting or ELISA) as  
15 method of detection. However, Western blotting is a time consuming procedure (approximately 2 days) and a semi-quantitative method with poor accuracy. As a result, this method cannot be used for detailed analysis of the amount and kinetics of cytochrome c release under differing conditions,  
20 and cannot be used for drug screening. On the other hand, ELISA quantification requires plate coating, use of pre-set formats and is not really user-friendly because of the multiple washing stages.

HPLC has also been used for the quantitation of cytochrome  
25 c. Compared to Western blotting, the HPLC method is able to provide quantitative data. However samples have to be quantified sequentially and each quantification requires 20 minutes at least.

30 The inventors have found that by using cytochrome c-specific agents it was possible to determine cytochrome c concentration in different sub-cellular fractions by an enzymatic method.

The aim of the invention is first to provide a tool to

accurately quantify cytochrome c concentration in biological samples. It is another object of the invention to provide a ready-made kit, for performing the described assay method.

According to the invention, the method requires:

- 5     - adding to the studied sample an efficient amount of two redox couples for a cycling oxydo-reduction of cytochrome c, said couples consisting in an oxidizing agent, cytochrome c oxidase enzyme (COX), and a reducing agent specific for cytochrome c with a co-factor,
- 10    - measuring the oxidation of the co-factor which is oxidized during the redox cycle, the amount of the oxidative form thereof being correlated to the concentration of cytochrome c in the sample.

The cycling redox system which is generated enables a  
15 highly specific and sensitive detection of cytochrome c. The reducing agent specifically reduces cytochrome c and this reduction is detected by monitoring the concomitant oxidation of said co-factor. To amplify the signal due to the co-factor oxidation, the oxidizing agent, cytochrome c oxidase, is added  
20 to the reaction medium to re-oxidize cytochrome c, allowing this cytochrome c to be used again by the reducing agent. The cycling redox system which is generated is strictly dependent on the presence of cytochrome c. Accordingly the amplification of the co-factor oxidation indicates that cytochrome c is  
25 present in the tested sample.

The oxidation of the co-factor is handily measured by a biophysical system depending on the co-factor and allowing to distinguish the oxidized form from the reduced form (for  
example but not limited to, absorbance measurement by  
30 molecular absorption spectrophotometry at 340 nm for NADH or NADPH detection).

In a preferred embodiment of the invention, the reducing agent is NADH-cytochrome c reductase or NADPH-cytochrome c reductase and the co-factor is NADH or NADPH respectively.

Advantageously, said measurement is compared to measurements of known concentrations of standard cytochrome c.

Said oxidizing and reducing agents and co-factors are, for example but not limited to, under liquid, dried or lyophilised form and obtained by purification of recombinant or natural compounds or by chemical synthesis.

The detection may be performed on any biological sample suspected to contain cytochrome c, such as cellular extracts or organelles purified from primary cells, cell lines, tissues, blood, organs or tumors that may or may not have been submitted to stress, particularly apoptosis-inducing stress.

The detection is advantageously performed in supernatants obtained upon sedimenting mitochondria following incubation under various experimental conditions; or in cellular extracts obtained upon cytosol purification after cells incubation under various experimental conditions.

The invention also relates to a kit for detecting cytochrome c in sample to be tested. Such a kit, comprises:

- two redox couples for a cycling oxido-reduction of cytochrome c, said couples consisting in an oxidizing agent, i.e. cytochrome c oxidase enzyme, and a reducing agent, specific for cytochrome c, using a reduced co-factor.

The reducing agent is advantageously a NADH-cytochrome c reductase or NADPH-cytochrome c reductase and the co-factor is NADH or NADPH respectively.

In the said kit, said agents are, for example but not limited to, under liquid, dried or lyophilised form and obtained by purification of recombinant or natural compounds or by chemical synthesis.

Optionally, said kit further comprises a buffer.

Said kit also comprises standard cytochrome c as a reference.

Said means are advantageous substitutes to immuno-assay, HPLC detection or Western blotting in order to detect cytochrome c in biological samples.

The present invention is further illustrated by the following examples and figures, which respectively represent:

- Fig. 1: Cycling enzyme assay for the detection of cytochrome c;
- Fig. 2: NAD(P)H oxidation is dependent on the simultaneous presence of the various components of the enzymatic cycle and is fully blocked upon cytochrome c oxidase inhibition;
- Fig. 3: At constant cytochrome c concentration, the rate of the cycling reaction is dependent on the amount of added enzymes;
- Fig. 4: At saturating enzyme concentrations, the rate of the cycling assay only depends on cytochrome c concentration;
- Fig. 5: Saturating enzyme concentration permits to detect low concentration of cytochrome c in mitochondrial supernatants.

In the current embodiment of the invention, measurements are performed in transparent flat-bottom 96-well microplates in a final volume of 220 microliter. Enzymes, prepared enzyme buffer (10 mM Tris-HCl, pH 7.0, 250 mM saccharose), were added (20 microliter per well) to 180 microliter assay buffer (10 mM Tris-HCl, pH 7.0, 120 mM KCl, 300  $\mu$ M NADH or NADPH). The reaction is started by adding 20 microliter of either purified cytochrome c or desired sample to obtain a final volume of 220 microliter.

NADH or NADPH oxidation is spectrophotometrically measured at 340 nm, as both NADH and NADPH absorb at this wavelength while  $\text{NAD}^+$  and  $\text{NADP}^+$  do not. For the determination of the rate of co-factor oxidation, absorbance is monitored in kinetic mode for 30 minutes at room temperature.

$$\text{Rate of NADH consumption (M/min)} = \frac{(\text{DO}_{t=180s} - \text{DO}_{t=1800s}) * 60}{(1800-180) * 6230}$$

5 Stock solution of cytochrome c and NADH or NADPH are prepared in distilled water.

Cycling enzyme assay for the detection of cytochrome c (fig. 1).

Enzyme A is a cytochrome c reductase that catalyses  
10 cytochrome c reduction and concomitant co-factor (NADH or NADPH) oxidation. Oxidized cytochrome c is thus reduced by the reductase. Enzyme B is the cytochrome c oxidase: it oxidizes reduced cytochrome c and transfers electron to molecular oxygen. The presence of both enzymes allows for a redox cycle  
15 using cytochrome c. The rate of cycling becomes limited by cytochrome c in the presence of an excess of both enzymes. The rate of NAD(P)H oxidation is then directly proportionnal to the amount of available cytochrome c. Cyanide (KCN) is a cytochrome c oxidase inhibitor.

20 NAD(P)H oxidation is dependent on the simultaneous presence of the various components of the enzymatic cycle and is fully blocked upon cytochrome c oxidase inhibition. Measurements are performed by absorption spectrophotometry at 340 nm (fig.2).

Complete medium : 300  $\mu$ M NADH, 300  $\mu$ U NADH-cytochrome c  
25 reductase, 300  $\mu$ U cytochrome c oxidase, 2  $\mu$ M cytochrome c; 1. NADH only; 2. Complete medium without cytochrome c oxidase; 3. Complete medium without cytochrome c; 4. Complete medium without NADH-cytochrome c reductase; 5. Complete medium added with 500  $\mu$ M KCN as to inhibits cytochrome c oxidase; 6.  
30 Complete medium; noticeably, the absence of any of the components hampers cycle operation, except for the absence of added NADH-cytochrome c reductase, due to the contamination of cytochrome c oxidase preparation by NADH-cytochrome c reductase.

At constant cytochrome c concentration, the rate of the cycling reaction is dependent on the amount of added enzymes. Measurements are performed by absorption spectrophotometry at 340 nm (fig.3).

5 In the low range of enzyme concentrations, the oxidation of NADH (300  $\mu$ M) correlates with enzyme concentration. In the selected example, NADH-cytochrome c reductase is in excess compared to cytochrome c oxidase, and the rate of the reaction is dependent on this latter enzyme. A large excess of both  
10 enzymes is therefore required to avoid any interference that may result from enzymes potentially added with studied samples.

At saturating enzyme concentrations, the rate of the cycling assay only depends on cytochrome c concentration. Measurements  
15 are performed by absorption spectrophotometry at 340 nm (Fig.4).

At high enzyme concentrations (240  $\mu$ U NADH-cytochrome c reductase, 240  $\mu$ U cytochrome c oxidase/well), NADH (300  $\mu$ M) is oxidized proportionally to the cytochrome c concentration. For  
20 low cytochrome c concentrations, a linear relationship exists between the rate of NADH consumption and the cytochrome c concentration. It makes this reaction a simple and convenient method to quantify cytochrome c.

Saturating enzyme concentration permits to detect low  
25 concentration of cytochrome c in mitochondrial supernatants. Measurements are performed by absorption spectrophotometry at 340 nm (Fig. 5).

Preparation and incubation of mitochondria: Mouse liver mitochondria were prepared by a standard procedure with slight  
30 modifications. Briefly, the minced liver was homogenized in medium A (0.3 M saccharose, 0.2 mM EGTA and 5 mM TES, pH 7.2). Homogenates were centrifuged at low speed (760 g, 10 min, at 4°C), collected supernatants diluted in medium A and further centrifuged (8740 g, 10 min at 4°C). Washed mitochondria were

layered on top of two successive Percoll gradients, consisting of three layers of 18%, 30% and 60% (w/v) Percoll in medium B (0.3 M saccharose, 0.2 mM EGTA, 10 mM TE; pH 6.9). After centrifugation (9740 g, 10 min), the fraction containing  
5 intact mitochondria was collected from the 30%/60% interface, washed with medium A (8740 g, 10 min) and the pellet resuspended in 500  $\mu$ L medium A. Protein concentration was determined by BCA assay.

Purified mitochondria (4 mg protein/mL) were then  
10 incubated in medium C (0.2 M saccharose, 5 mM succinate, 10  $\mu$ M EGTA, 1 mM  $H_3PO_4$ , 2  $\mu$ M Rotenone and 10 mM Tris-MOPS; pH 7.4) for 30 min at room temperature with 500  $\mu$ M calcium chloride or 5  $\mu$ g/mL alamethicin as inducers of cytochrome c release.

Preparation of samples: Treated mitochondria were  
15 centrifuged (6800 g, 10 min at 4°C) and supernatants were about 20 fold-concentrated on 10,000 Da concentrator microtubes for 15 min at 12,000 g, room temperature. Each sample (20 microliter) was added to 200 microliter reaction solution (300  $\mu$ M NADH in 180  $\mu$ L assay buffer, 1 mU NADH-  
20 cytochrome c reductase in 10  $\mu$ L enzyme buffer, 1 mU cytochrome c oxidase in 10  $\mu$ L enzyme buffer); 1. Distilled water; 2. Purified cytochrome c 100 nM; 3. Supernatant of intact purified mitochondria; 4. Supernatant from calcium-treated mitochondria; 5. Supernatant from alamethicin-treated  
25 mitochondria. This set of experiments establishes that the proposed cycling enzyme assay is sensitive enough as to quantify cytochrome c released from mitochondrial preparations.